This launch is the first part of an alliance in which Taylor and Baxter will jointly develop, manufacture and market four injectable products with current sales in excess of $200 million: Ketorolac Tromethamine Injection, Amrinone Lactate Injection, Diltiazem HCl Injection and Labetalol HCl Injection.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.